Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients

被引:43
|
作者
Selabe, S. Gloria
Lukhwareni, Azwidowi
Song, Ernest
Leeuw, Yeegan G. M.
Burnett, Rosemary J.
Mphahlele, M. Jeffrey
机构
[1] Univ Limpopo, Dept Virol, HIV & Hepatitis Res Unit, Pretoria, South Africa
[2] Johannesburg Hosp, Hepatol Div, Dept Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Margarita Hlth Ctr, Pretoria, South Africa
关键词
lamivudine-resistant HBV strains; hepatitis B virus; human immunodeficiency virus; HBV-HIV coinfection; sub-Saharan Africa;
D O I
10.1002/jmv.20974
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This was an exploratory study to investigate larnivudine-resistant hepatitis 13 virus (HBV) strains in selected lamivudine-naive HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-naive HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HlV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg-positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor((R)) test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-naive HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and < 200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
引用
收藏
页码:1650 / 1654
页数:5
相关论文
共 50 条
  • [31] Hepatitis delta in HIV/HBV co-infected patients in Brazil: is it important?
    Mendes-Correa, Maria Cassia
    Gomes-Gouvea, Michele S.
    Alvarado-Mora, Monica V.
    Da Silva, Mariliza H.
    Lazari, Carolina
    Cavalcanti, Norma C. S.
    Alonso, Flaviane K.
    Carpinelli, Catia C.
    Uip, David E.
    Pinho, Joao R. R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (12) : E828 - E832
  • [32] Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study
    Amponsah-Dacosta, Edina
    Rakgole, J. Nare
    Gededzha, Maemu P.
    Lukhwareni, Azwidowi
    Blackard, Jason T.
    Selabe, Selokela G.
    Mphahlele, M. Jeffrey
    INFECTION GENETICS AND EVOLUTION, 2016, 43 : 232 - 238
  • [33] Characterization of hepatitis B virus mutations in untreated patients co-infected with HIV and HBV based on complete genome sequencing
    Tangkijvanich, Pisit
    Sa-Nguanmoo, Pattaratida
    Avihingsanon, Anchalee
    Ruxrungtham, Kiat
    Poovorawan, Kittiyod
    Poovorawan, Yong
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (01) : 16 - 25
  • [34] Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?
    Rancinan, C
    Neau, D
    Savès, M
    Lawson-Ayayi, S
    Bonnet, F
    Mercié, P
    Dupon, M
    Couzigou, P
    Dabis, F
    Chêne, G
    AIDS, 2002, 16 (10) : 1357 - 1362
  • [35] The treatment outcome of chronic HBV infection among HBV/HIV co-infected and HBV mono-infected patients
    Karic, Uros
    Milosevic, Ivana
    Pesic-Pavlovic, Ivana
    Salemovic, Dubravka
    Stojkovic, Milan
    Jevtovic, Djordje
    INTERNATIONAL JOURNAL OF STD & AIDS, 2020, 31 (01) : 38 - 45
  • [36] Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy
    Mohareb, Amir M.
    Kouame, Gerard Menan
    Gabassi, Audrey
    Gabillard, Delphine
    Moh, Raoul
    Badje, Anani
    Emieme, Arlette
    Maylin, Sarah
    Menan, Herve
    Hyle, Emily P.
    Delaugerre, Constance
    Danel, Christine
    Anglaret, Xavier
    Lacombe, Karine
    Eholie, Serge P.
    Boyd, Anders
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (04) : 621 - 629
  • [37] Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in the Gambia, West Africa
    Stewart B.
    Jobarteh M.L.
    Sarge-Njie R.
    Alabi A.
    De Silva T.
    Peterson K.
    Peterson I.
    Whittle H.
    Rowland-Jones S.
    Jaye A.
    Cotten M.
    Mendy M.
    BMC Research Notes, 4 (1)
  • [38] Evaluation of HBV serological markers in treatment-naive HBV mono-infected patients and HBV-HIV co-infected patients
    Jiang, Bei
    Su, Rui
    Ren, Doudou
    Zheng, Xiaoya
    Cao, Yu
    Mi, Yuqiang
    Wang, Fengmei
    Ma, Ping
    VIRUS RESEARCH, 2020, 290
  • [39] The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients
    Gelinck, LBS
    Claas, ECJ
    Kroon, FP
    JOURNAL OF HEPATOLOGY, 2005, 43 (02) : 360 - 361
  • [40] Effectiveness of lamivudine in a cohort of HIV and hepatitis B co-infected patients
    Lafuente-Lafuente, C.
    Schnepf, N.
    Jarrin, I.
    Mazeron, M. C.
    Diemer, M.
    Bendenoun, M.
    Mouly, S.
    Delcey, V.
    Sellier, P.
    Bergmann, J. F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 33 - 33